PLX-300

PLX-300 is a novel small molecule drug, originally isolated from cinnamon and also present in various foods such as vegetables, fruits, honey, and whole grains. It acts as an agonist of peroxisome proliferator-activated receptor alpha (PPARα), leading to increased production of transcription factor EB (TFEB), which promotes lysosome biogenesis. This mechanism is believed to reduce inflammation and prevent apoptosis (cell death), providing neuroprotective effects relevant for lysosomal storage disorders. The drug has received both Rare Pediatric Disease and Orphan Drug designations from the FDA for several rare diseases including Krabbe disease (Globoid cell leukodystrophy), GM2 gangliosidoses (Tay-Sachs disease, Sandhoff disease), Niemann-Pick disease type A, and Niemann-Pick disease type B[1][3][5][7]. Preclinical studies have shown proof-of-concept efficacy in animal models of these diseases.